Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

622
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
622
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

540
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
540
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

617
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
617
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

645
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
645
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

493
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
493

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Navigating Human Astrocyte Differentiation: Direct and Rapid One-Step Differentiation of Induced Pluripotent Stem Cells to Functional Astrocytes Supporting Neuronal Network Development.

Glia·2026
Same author

Impact of RASopathy subtype on the early disease course of RASopathy-associated hypertrophic cardiomyopathy: clinical outcomes and genetic insights.

Pediatric research·2026
Same author

Microaffirmations, counterspaces, and mental health: Supporting Black male students at Predominantly White Institutions.

Cultural diversity & ethnic minority psychology·2026
Same author

Cell death regulation: A novel way of natural products to treat myocardial hypertrophy.

Ageing research reviews·2026
Same author

Residual Inflammatory Risk in Atherosclerotic Cardiovascular Disease: Are We Ready for Targeted Therapies?

The Canadian journal of cardiology·2026
Same author

Pathological disruption of CELF2 shuttling causes neuronal hyperactivity, learning deficits, and seizures.

The Journal of clinical investigation·2026

関連する実験動画

Updated: Feb 20, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

異常な脂質シグナル伝達が,小児性心筋病におけるダイアストリック機能不全を特徴づけている.

Andrei L Turinsky1, Nour Hanafi1, Abdelrahman Said2

  • 1Centre for Computational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.

JACC. Basic to translational science
|February 18, 2026
PubMed
まとめ

小児性心筋症は,不明確なメカニズムによって,心不全を引き起こす. 異常な脂質シグナル伝達と心臓筋細胞の蓄積が鍵であり,セマグルチドを子供の心臓病の潜在的な治療法として提供しています.

キーワード:
RNAのシーケンシングカーディオミオパシー カーディオミオパシーディアストロリック機能不全iPSC カーディオミオサイトリピドーム (lipidome) とはマルチオミックス (Multiomics) とは

さらに関連する動画

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K

関連する実験動画

Last Updated: Feb 20, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K

科学分野:

  • 心臓病学 心臓病学
  • メタボロミクスとは
  • 分子生物学は分子生物学である.

背景:

  • 小児性心筋症は,ダイアストリック心不全の重要な原因です.
  • この状態の根本的な分子メカニズム,特に腹動機能不全は十分に理解されていません.
  • 特定の分子シグネチャーを特定することは,標的治療の開発に不可欠です.

研究 の 目的:

  • 小児性心筋疾患におけるダイアストリック機能不全の分子メカニズムを調査する.
  • ダイアストリック機能不全に関連した異なった代謝およびトランスクリプトミックのサインを特定する.
  • 小児性心筋病の潜在的治療標的を調査する.

主な方法:

  • 全球心筋トランスクリプトミクスと血液脂質ミクスプロファイリングが行われました.
  • 診断された遺伝子マーカーを使用して,静脈動脈機能不全を分類するために,機械学習モデルが開発されました.
  • 誘導された患者からの多能幹細胞由来心筋細胞は,脂質蓄積とミトコンドリア機能について分析されました.
  • 細胞機能不全を救済するセマグルチドの有効性が評価されました.

主要な成果:

  • 制御不能な脂質シグナル伝達によって特徴づけられるユニークな代謝シグネチャーは,下痢性機能不全で特定されました.
  • 過剰な飽和脂質と脂質酸化障害は,心筋の遺伝子発現の変化と相関しています.
  • 機械学習モデルは,異なる心筋病変のサブタイプを介して,直立性機能不全を正確に分類しました.
  • 患者に由来する心筋細胞は,脂質の蓄積とミトコンドリア機能障害を示し,これはセマグルチド治療によって改善された.

結論:

  • 小児性心筋病におけるダイアストリック機能不全は,異常な脂質シグナル伝達を含む独特の分子現象型と関連しています.
  • 脂質代謝障害とミトコンドリア機能障害は,この状態の重要な特徴です.
  • 潜在的にセマグルチドのような薬剤を用いた異常な脂質シグナル伝達をターゲットにすることは,小児性心筋病に対する有望な治療戦略を表しています.